{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:02:13Z","timestamp":1789768933821,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.014","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:19:03Z","timestamp":1789766343000},"page":"866-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-4852","authenticated-orcid":false,"given":"James R.","family":"Janopaul-Naylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatraya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil T.","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Hershatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pretesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashesh B.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-2096","authenticated-orcid":false,"given":"Sagar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.08.014_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.urolonc.2026.08.014_bib0002","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.014_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2018.06.037","article-title":"National trends in active surveillance for prostate cancer: validation of Medicare claims-based algorithms","volume":"120","author":"Modi","year":"2018","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.014_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.014_bib0005","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.014_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.014_bib0007","doi-asserted-by":"crossref","first-page":"467.e1","DOI":"10.1016\/j.clgc.2021.03.014","article-title":"Risk of cognitive effects in comorbid patients with prostate cancer treated with androgen receptor inhibitors","volume":"19","author":"Morgans","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2026.08.014_bib0008","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102340","article-title":"Modifiable cardiovascular risk factors amongst men with and without prostate cancer in a large, prospective registry","volume":"23","author":"Janopaul-Naylor","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"27","key":"10.1016\/j.urolonc.2026.08.014_bib0010","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.014_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.urolonc.2026.08.014_bib0013","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.08.014_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2026.08.014_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16482","article-title":"Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics","volume":"134","author":"Roberts","year":"2024","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.urolonc.2026.08.014_bib0016","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s40520-022-02213-w","article-title":"Advanced age portends poorer prognosis after radical prostatectomy: a single center experience","volume":"34","author":"Porcaro","year":"2022","journal-title":"Aging Clin Exp Res"},{"issue":"15","key":"10.1016\/j.urolonc.2026.08.014_bib0017","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2026.08.014_bib0018","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.014_bib0019","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.euf.2020.02.008","article-title":"Clinical-genomic characterization unveils more aggressive disease features in elderly prostate cancer patients with low-grade disease","volume":"7","author":"Goldberg","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.urolonc.2026.08.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29760","article-title":"Trends in active surveillance for men with intermediate-risk prostate cancer","volume":"7","author":"Diven","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.014_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279981","article-title":"Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study","volume":"18","author":"Chen","year":"2023","journal-title":"PLoS One"},{"issue":"4 Pt 1","key":"10.1016\/j.urolonc.2026.08.014_bib0022","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.juro.2007.05.135","article-title":"Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications","volume":"178","author":"Krupski","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.08.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110256","article-title":"Testosterone recovery after androgen deprivation therapy in localised prostate cancer: long-term data from two randomised trials","volume":"195","author":"Nabid","year":"2024","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.014_bib0024","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2020.06.017","article-title":"Impact of sequencing of androgen suppression and radiation therapy on testosterone recovery in localized prostate cancer","volume":"108","author":"Roy","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.014_bib0025","article-title":"Impact of androgen deprivation therapy on cognitive function of elderly men with prostate cancer","volume":"16","author":"Bassyouny","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad232","article-title":"What are the priorities for research of older people living in their own home, including those living with frailty? A systematic review and content analysis of studies reporting older people\u2019s priorities and unmet needs","volume":"53","author":"Graham","year":"2024","journal-title":"Age Ageing"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.014_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10433-021-00633-7","article-title":"What matters to people aged 80 and over regarding ambulatory care? A systematic review and meta-synthesis of qualitative studies","volume":"19","author":"Herrler","year":"2022","journal-title":"Eur J Ageing"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.014_bib0028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bju.15887","article-title":"Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial","volume":"131","author":"Shore","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.08.014_bib0029","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18433\/jpps31003","article-title":"Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Wang","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.urolonc.2026.08.014_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.627083","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Sung","year":"2021","journal-title":"Front Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:19:16Z","timestamp":1789766356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007076"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}